Clinical Trials
8 trialsNCT02489903 2025-03-17
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
Phase 2 Completed
NCT05583188 2024-07-19
VIGOR
Galvanize Therapeutics, Inc.
Phase 4 Terminated
NCT00054197 2020-10-05
Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
CTI BioPharma
Phase 3 Terminated
NCT01109524 2015-12-24
Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00148798 2014-06-25
FLEX
Merck KGaA, Darmstadt, Germany
Phase 3 Completed
NCT00055887 2013-05-10
Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer
Spectrum Pharmaceuticals, Inc
Phase 3 Withdrawn
NCT01839032 2013-04-24
Oral Vinorelbine as Induction Chemotherapy Followed Concomitant Chemoradiotherapy
Pierre Fabre Medicament
Phase 2 Completed
NCT00256711 2009-04-23
Phase II Iressa Versus Vinorelbine (INVITE)
AstraZeneca
Phase 2 Completed